DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00042471

CompletedPhase 2

Evaluation of the Bioavailability of Pramlintide

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

4

Recruiting sites

—

Enrollment

75

actual

Study population

Obesity / overweight, Type 1 diabetes, Type 2 diabetes

Key I/E criteria

•BMI 30-45•HbA1c 6-12%

Primary endpoint

•Effect of varying needle length on bioavailability of Pramlintide

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00042471
Org study ID137-153

Timeline

Milestones

Study first posted2002-08-01estimated
Last update posted2015-09-23estimated
Study start2002-06 (month precision)
Primary completion2002-12actual (month precision)
Study completion2002-12actual (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Obesity / overweightType 1 diabetesType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Eligibility criteria

•HbA1c value between 6-12%
•BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2
•Consistent insulin regimen for 2 months prior to screening

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint/low confidence

Effect of varying needle length on bioavailability of Pramlintide

Time frame:approximately 6days but not to exceed 14days

descriptive

Secondary/protocol endpoint

Effect of varying needle length on safety and tolerability of Pramlintide

Time frame:Approximately 6 days not to exceed 14days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.